Clinical Trial

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-17
notable Enrollment increased: 6 -> 7 participants 2026-06-17
Trial Details
NCT Number NCT07187375
Lead Sponsor Neurocrine Biosciences
Conditions Congenital Adrenal Hyperplasia
Enrollment 7 participants
Start Date 2025-09-30
Primary Completion 2029-09-06 (estimated)
Study Completion 2029-10-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-16